

Intranasal dantrolene nanoparticles inhibit lipopolysaccharide-induced depression and anxiety behavior in mice

Huafeng Wei

huafeng.wei@pennmedicine.upenn.edu

University of Pennsylvania Perelman School of Medicine

Jia Liu

Yan Lu

Piplu Bhuiyan

Jacob Gruttner

Lauren St. Louis

Yutong Yi

Ge Liang

Article

Keywords:

Posted Date: April 3rd, 2025

DOI: <https://doi.org/10.21203/rs.3.rs-6254774/v1>

License:   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Additional Declarations: Yes Huafeng Wei is an inventor for patents application in USA and other countries, proposing intranasal dantrolene nanoparticles to treat dementia and depression in Alzheimer's disease.

Version of Record: A version of this preprint was published at Translational Psychiatry on February 3rd, 2026. See the published version at <https://doi.org/10.1038/s41398-026-03816-x>.

Abstract

This study investigates the therapeutic effectiveness of intranasal dantrolene nanoparticles pretreatment to inhibit lipopolysaccharide (LPS)-induced pathological inflammation and synapse destruction and depressive and anxiety behavior in mice. B6SJLF1/J adult mice were pretreated with intranasal dantrolene nanoparticles (dantrolene: 5mg/kg), daily, Monday to Friday, 5 days per week, for 4 weeks. Then, mice were treated with an intraperitoneal injection of LPS (5mg/kg) for one time. Behavioral tests for depression and anxiety were performed 24 hours after a one-time LPS injection. Biomarkers for pyroptosis-related inflammation cytokines (IL-1 β and IL-18) in the blood and brain were measured using enzyme-linked immunosorbent assay (ELISA) and immunoblotting, respectively. The changes of primary proteins activation inflammatory pyroptosis (NLRP3: NLR family pyrin domain containing 3, Caspase-1, N-GSDMD: N terminal protein gasdermin D) and synapse proteins (PSD-95 and synpatin-1) in brains were measured using immunoblotting. Intranasal dantrolene nanoparticles robustly inhibited LPS-induced depression and anxiety behavior. Intranasal dantrolene nanoparticles significantly inhibited LPS-induced pathological elevation of IL-1 β and IL-18 in the blood and brain and inhibited LPS-induced activation of pyroptosis. Intranasal dantrolene nanoparticles significantly ameliorated decrease of PSD-95 and synpatin-1 proteins in brains. Thus, intranasal dantrolene nanoparticles have demonstrated neuroprotection against inflammation-mediated depression and anxiety behaviors and should be studied further as a future effective drug treatment of major depression disorder or anxiety psychiatric disorder.

Introduction

Three hundred million people worldwide suffer from major depressive disorder (MDD)¹. MDD is a chronic and recurrent disease affecting about 20% of the population and the leading cause of suicide². MDD imposes a tremendous psychological burden, as well as significant social repercussions and contributions to other disabilities³. The expected direct and indirect costs of MDD are up to \$6 trillion in the USA alone⁴. An estimated 4% of the global population currently experience an anxiety disorder. In 2019, 301 million people in the world had an anxiety disorder, with a lifetime prevalence of approximately 34 percent⁵. Major depression disorder and anxiety disorders were approximately twice as prevalent among women^{6,7}, with overall age-specific rates remaining relatively stable or increasing across the lifespan⁸. In 2021, an estimated 5.8 million (9.4%) children and adolescents were impacted by anxiety⁹. Depression and anxiety often co-exist and are the most common psychiatric diseases, which are chronic diseases with unclear mechanisms of pathology¹⁰.

Classical treatment of depression or anxiety psychiatric disorders includes atypical antipsychotics that modulate dopamine and serotonin neurotransmission^{11,12}. Pharmacotherapies for anxiety disorders also include drugs that interact with GABA neurotransmission systems¹³. Unfortunately, antidepressants have significant limitations, including slow onset of action, high rates of nonresponse, and acute worsening of anxiety¹⁴. Benzodiazepines are not recommended for long-term use in some anxiety

disorders, due to concerns about their potential for abuse, tolerance, and withdrawal, and they are ineffective in some anxiety spectrum disorders¹⁵. Treatment of MDD is prone to a high risk of resistance (up to 30% of patients are unresponsive to the first treatment) and relapse (up to 8%)^{3,10}. Treatment-resistant anxiety with remission rates may be as low as 25–35%, and relapse rates post remission may be 30% after 10 years¹⁶. Thus, there is an urgent need to develop novel approaches to treat depression and anxiety, especially treatment-resistant depression, or anxiety, with minimal side effects or organ toxicity.

Increasing studies indicated that glutamate neurotransmission plays a critical role in mood function and its imbalance may cause psychiatric disorders¹⁷. Glutamate is linked to the development of anxiety disorders through its regulation of neuropeptides, fear extinction, and stress response. Glutamate is also important in synaptic and neural plasticity related to psychiatric disorders. Ketamine, an N-methyl-d-aspartate (NMDA) glutamate receptor antagonist, was approved in 1970 by the Food and Drug Administration (FDA) for use in children and adults as an anesthetic. Recent studies indicate that ketamine is effective in treating MDD, especially treatment-resistant depression (TRD)^{18,19}. Ketamine is also effective in treating anxiety disorders, even those resistant to traditional treatments^{9,20}. While traditional antidepressants can take weeks to months to have an effect, ketamine has rapid effects on mood and suicidality, with mood changes reported as early as the first 4 hours after treatment²¹. As an antagonist of NMDAR, a primary glutamate receptor on the plasma membrane that causes Ca^{2+} influx into the cytosol from extracellular space, ketamine has become a safe and broadly effective drug to treat depression or anxiety disorders, so is the intranasal esketamine²². This indicates that glutamate-mediated excitotoxicity and associated disruption of intracellular Ca^{2+} homeostasis play a key role in the pathology of depression and anxiety disorders.

Although molecular mechanisms are unclear, increasing evidence suggests that upstream disruption of intracellular Ca^{2+} homeostasis and associated downstream inflammation and synapse dysfunction play critical roles in MDD pathologies^{23–25}, as well as anxiety disorder^{26,27}. The overactivation of ryanodine receptors (RyRs) in MDD and associated excessive Ca^{2+} release from endoplasmic reticulum (ER) results in depletion of ER Ca^{2+} and pathological elevation of cytosol and mitochondrial Ca^{2+} concentrations, detrimental to synapse function and cell survival^{25,28,29}. RyRs overactivation have also been shown to increase anxious behavior²⁸. Upstream Ca^{2+} dysregulation results in mitochondria dysfunction³⁰, mitochondrial and cellular oxidative stress^{10,31}, activation of inflammasomes, and cell or neuron death by pyroptosis^{32–35}. This results in the release of inflammatory cytokines (IL-1 β and IL-18) and pathological inflammation-mediated cell death by pyroptosis^{34,36}. Pathological cytokines, especially pyroptosis-related IL-18 play important roles in psychiatric disorders^{37,38}. Gut dysbiosis and associated inflammation also contribute to pathology in depression and anxiety behaviors^{39,40}. Thus, a drug that inhibits upstream Ca^{2+} dysregulation and then downstream pathological inflammation and programmed

cell death by pyroptosis and synapse destruction is expected to treat MDD and anxiety disorder effectively.

Dantrolene, a RyRs antagonist, is a US Food and Drug Administration-approved drug for the treatment of malignant hyperthermia, muscle spasms, and neuroleptic syndrome, with tolerable side effects and occasional liver toxicity at high doses⁴¹. Dantrolene, with its ability to inhibit the common upstream critical Ca^{2+} dysregulation, is neuroprotective against many neurodegenerative diseases, including cerebral ischemia^{42,43}, Huntington's disease⁴⁴, spinocerebellar ataxia⁴⁵, amyotrophic lateral sclerosis⁴⁶, and seizures^{47,48}. Dantrolene robustly inhibited up to 78% of NMDA-induced elevation of cytosolic Ca^{2+} concentration in cerebral cortical neurons⁴⁹, suggesting it may have great potential to treat major depression disorder with a similar molecular mechanism of ketamine⁵⁰, which needs to be studied urgently.

In this study, we investigated the therapeutic effectiveness and the potential mechanisms of intranasal dantrolene nanoparticles on depression and anxiety behavior associated with pathological inflammation in adult mice. We induced inflammation by intraperitoneal injection of LPS. Our results demonstrated that intranasal dantrolene nanoparticles for twelve consecutive weeks robustly inhibited LPS-induced depression and anxiety behaviors in adult mice. These beneficial effects of intranasal dantrolene nanoparticles treatment were associated with its robust and significant inhibition of LPS-induced pathological elevation of pyroptosis-related inflammation cytokine of IL-1 β and IL-18 in blood and brains and loss of synapse proteins (PSD-95 and synpatin-1) in brains. This study provides proof of concept that intranasal dantrolene nanoparticles may be an effective treatment for depression and anxiety psychiatric disorders, potentially by inhibiting pathological inflammation and synapse destruction in the CNS.

Materials and methods

Animals

All procedures were approved by the Institutional Animal Care and Use Committee (IACUC) at the University of Pennsylvania. All B6SJLF1/J adult mice were obtained from Jackson Lab. Mice were divided into different cages according to age and gender, with no more than five mice per cage. Both male and female mice were used in this study.

Experimental treatment groups

As demonstrated in supplemental Fig. 1, adult male and female mice (5–10 months old) were randomly divided into different experimental groups. The mice were pretreated with either intranasal dantrolene nanoparticles (IN Dan, 5mg/kg) or vehicle (Veh), once a day, 5X/week (Monday through Friday). Control groups received no pretreatment. Fresh dantrolene nanoparticles were made every time before

administration. Intranasal dantrolene nanoparticles stock solution was made at 5 mg/ml. The Ryanodex formulation vehicle was made fresh and contained all inactive ingredients in Ryanodex^{51,52}. At the end of the 4-week pretreatment period, mice were treated with a one-time intraperitoneal injection of lipopolysaccharide (LPS, 5 mg/kg). Mice in the control group, without pretreatment, were treated with LPS (LPS, 5mg/kg) once as well. The sham control group received no pretreatment or treatment. At 24 hours following the one-time LPS treatment, behavioral tests for depression or anxiety behaviors were performed on all mice, with the following order of least to most stressful tests: OPT, EPMT, TST, and FST. Thereafter, all mice were euthanized, and the blood or brain was harvested for examination of inflammation and programmed cell death by pyroptosis and synapse destruction in the blood and brains.

Intranasal dantrolene nanoparticle or vehicle administration

Dantrolene (Sigma, St Louis, MO) was dissolved in the Ryanodex Formulation Vehicle (RFV: 125 mg mannitol, 25 mg polysorbate 80, 4mg povidone K12 in 5mL of sterile water and pH adjusted to 10.3), similar to our previous publications^{52,53}. For intranasal administration, the final concentration of dantrolene was 5 mg/mL as we have previously described. Mice were held and fixed by the scruff of their necks with one hand. With the other hand, mice were given a total of 1μL/gram of body weight of dantrolene nanoparticles or RFV. Accordingly, a mouse weighing 20 g would be given 20μL of solution, equal to a dantrolene dose at 5mg/kg. The solution was slowly delivered directly into the mouse's nose. Care was taken to ensure that mice were minimally stressed, and that the solution remained in the nasal cavity and did not enter the stomach or lungs.

Forced swimming test (FST)

Depression behavior was assessed using the FST, as described previously with some modification⁵⁴. The mice from each group were settled in a clear glass tank of 25 cm height, 10 cm diameter, 15 cm water depth, and (23 ± 2) °C water temperature. The test's total period was 6 minutes, 2 minutes for adaptation, and the total immobility time was recorded in the next 4 minutes. Immobility occurred when the mice discontinued floundering on the surface of the water, instead appearing as floating in an equilibrium state. The greater the immobility time, the more severe the depression behavior.

Tail suspension test (TST)

Depression behavior was assessed using the tail suspension test described previously, with modifications⁵⁵. We use specially manufactured tail suspension boxes, made of cartons with the dimensions (42 cm height X 18 cm width X 30 cm depth). To prevent animals from observing or interacting with each other, each mouse was suspended within its three-walled rectangular box. Each day, animals were acclimated to the testing room for at least 1 hour before the test. Each mouse was suspended in the middle of the box. The width and depth of the box were sufficiently sized to prevent the mouse from contacting the walls. In this setting, the approximate distance between the mouse's nose

and the apparatus floor was 20–25 cm. A plastic suspension bar (50 cm. height X 40 cm. depth), was used to suspend the tail of each mouse and positioned on the top of the box. At the bottom of each box, we placed a paper towel to collect feces or urine from the animals. A dark grey box was used for albino animals and a white colored box for mice of other coat colors. Before evaluation, the tail of the mouse was securely adhered to the suspension bar, which was able to withstand the mouse's weight. A video camera was placed in position and started recording the TST session. The total duration of the test was 6 minutes. The paper towel was replaced after each trial. After all sessions were finished, Any-maze software (Stoelting, USA) was used to analyze the collected data.

During the behavioral analysis, the mobility time of each mouse was measured and subtracted from 360 seconds, producing the immobility time. The investigator was blinded to the animal groups. The higher immobility time, the more severe the depressive behavior.

Open field test (OFT)

The OFT was performed as previously described to evaluate anxiety behavior as described⁵⁶. Each mouse was placed individually into the OFT apparatus (44 × 44 × 44 cm³), facing the wall. The locomotor activity was recorded for six minutes with a camera above the apparatus under dim light. The anxiety behavior of each mouse was measured using the total distance traveled, center entries, immobility time, and time spent in the central zone. After each test, the apparatus was cleaned with 75% ethanol. Any-maze software (Stoelting USA) was used to analyze the collected data. The lesser the central zone distance and mean speed, the higher the anxiety behavior. The higher immobility time, the more severe the anxiety behavior.

Elevated plus maze test (EPMT)

Anxiety was also assessed using EPMT, as described previously, although with some modification⁵⁷. Mice were placed in the center of an elevated plus-maze (arms are 33 cm × 5 cm, with 25 cm tall walls on the closed arms) under dim lighting and their behavior was videotaped for 5 minutes. We used Any-maze software (Stoelting USA) to analyze the collected data. The time spent in the closed and open arms, as well as the number of explorations of open arms, was measured and recorded. The more time spent in closed arms, the more severe the anxiety behavior.

Euthanasia and tissue collection

Mice were euthanized after the completion of all behavioral tests. As described previously⁵², mice were deeply anesthetized with 2–4% isoflurane delivered through a nose cone, with the concentration adjusted according to response to a toe pinch. The skin of each mouse was prepared, and an incision was made to open the chest and expose the heart. Blood was collected from the heart for the serum study using a syringe equipped with a 27G needle. The blood was centrifuged at 1400 rpm at 4°C for 30

min, and the supernatant was collected and frozen at -80°C . The mice were euthanized by trans-cardial perfusion and exsanguination was conducted with cold phosphate-buffered saline.

Measurements of serum concentration of IL-1 β and IL-18

We measured the serum IL-1 β and IL-18 cytokines using an ELISA kit, following company instructions, and as we described previously for measurement of S100 β , with some modification^{58,59}. All reagents and samples (the supernatant of the blood) were thawed to room temperature ($18-25^{\circ}\text{C}$) before use. It is recommended that all standards and samples be run at least in duplicate. Add 100 μL of each standard and sample into appropriate wells. Cover wells and incubate for 2.5 hours at room temperature or overnight at 4°C with gentle shaking. Discard the solution and wash it 4 times with 1X Wash Solution. Wash by filling each well with Wash Buffer (300 μL) using a multi-channel Pipette or auto washer. Complete removal of liquid at each step is essential to reliable performance. After the last wash, remove any remaining Wash Buffer by aspirating or decanting. Invert the plate and blot it against clean paper towels. Add 100 μL of 1x prepared Detection Antibody to each well. Cover wells and incubate for 1 hour at room temperature with gentle shaking. Discard the solution. Repeat the wash procedure as in step 3. Add 100 μL of prepared Streptavidin solution to each well. Cover wells and incubate for 45 minutes at room temperature with gentle shaking. Discard the solution. Repeat the wash as in step 3. Add 100 μL of TMB One-Step Substrate Reagent (Item H) to each well. Cover wells and incubate for 30 minutes at room temperature in the dark with gentle shaking. Add 50 μL of Stop Solution (Item I) to each well. Read absorbance at 450 nm immediately. Mouse IL-1 beta ELISA Kit and Mouse IL18 ELISA Kit come from SIGMA(RAB0275-1KT/RAB08100-1KT).

Immunoblotting (Western Blot)

As we described previously⁶⁰, total brain tissues were extracted by homogenization using cold RIPA buffer (#9806S, Cell Technology, USA) supplemented with protease inhibitor cocktails (P8340 Roche). The brain homogenates were rocked at 4°C for 90 minutes and then centrifuged at 14 000 rpm (Brushless Microcentrifuge, Denville 260D) for 20 minutes at 4°C to remove cell debris. After collecting the supernatant, the protein concentration was measured using a BCA protein assay kit (Pierce, Rockford, IL 61101 USA). Briefly, equal amounts of protein (20 μg /lane) were loaded onto 4–20% gel electrophoresis of mini-protein TGX precast (Cat. #4561094, BIO-RAD) and transferred to polyvinylidene difluoride (PVDF) membranes (Immobilon-P, MERK Millipore, Ireland) using wet electrotransfer system (BIO-RAD, USA). Following the transfer membrane blocking with 5% BSA (Sigma-Aldrich) for 1 hour, then the PVDF membrane was incubated with primary antibodies overnight at 4°C including NLRP3, cleaved caspase-1, GSDMD-NT, IL-1 β , IL-18, PSD95, Synapsin-1, GAPDH (Table 1). Then, the membranes were incubated with a secondary antibody including anti-Mouse IgG1 HRP-linked; Anti-rabbit IgG, HRP-linked that was conjugated to horseradish peroxidase and washed with Tris-buffered saline containing 0.2% Tween-20 (TBST). Following that, TBST was used for washing the membranes three times for 10 minutes. After incubation with secondary antibodies, protein bands were visualized using ECL Western

Blotting Detection Reagents (Cytiva, amersham, UK) and quantified for band intensity using ImageJ software (National Institutes of Health, Bethesda, MD, USA), by two persons blinded to treatments and averaged for each mouse.

Table 1

	Cat. and Manufacture	Dilution
Primary antibody		
Anti- NLRP3	68102-1-Ig; Proteintech	1:2 000
Anti-Human procaspase-1/ cleaved caspase-1 p20	#2225S, Cell signaling Technology,USA	1:1 000
Anti- Cleaved GSDMD	#36425S; Cell signaling Technology, USA	1:1 000
Anti-IL-1β	31202S, Cell signaling Technology, USA	1:1 000
Anti-IL-18	10663-1-AP; Proteintech	1:3 000
Anti-PSD95	#2507; Cell signaling Technology, USA	1:1 000
Anti-Synapsin-1	#5297; Cell signaling Technology, USA	1:1 000
GAPDH	MA5–15738, Thermo Fisher Scientific	1:10 000
Secondary antibody		
Anti-Mouse IgG1; HRP -linked	# PA1-74421, Thermo Fisher Scientific	1:10 000
Anti-rabbit IgG, HRP-linked	#7074; Cell signaling Technology, USA	1:1 000

Statistical Analysis

All data were represented as mean ± standard deviations (Means ± SD). Statistical analyses were employed with GraphPad Prism (Version 9.3.1, CA, USA). Comparisons of more than two groups were conducted by one-way ANOVA with Tukey’s multiple comparison test. The N values in each group represent the number of mice. P < 0.05 was considered statistically significant.

Results

Intranasal dantrolene nanoparticle pretreatment significantly inhibited LPS-induced helplessness and anxiety-related behaviors.

The FST and TST tests are commonly used to evaluate helplessness or depression behaviors in mice and to test the drug’s efficacy versus side effects^{27,61,62}. In both FST (Fig. 1A) and TST (Fig. 1B), LPS

induced significantly increased immobile times (helplessness or depression behaviors) by 89% (60.1 vs. 113.3) and 90% (98.1 vs. 186.6) respectively. Intranasal dantrolene nanoparticle pretreatment robustly inhibited the increased immobile time in FST by 41% (113.3 vs. 66.9) and in TST by 46% (186.6 vs. 101.5). In contrast, the intranasal dantrolene nanoparticles vehicle control did not demonstrate the same inhibitory effects on helplessness behaviors. The elevated plus maze test (EPMT) and open field test (OPT) are commonly used to evaluate anxiety-related behaviors in mice and test drug efficacy to treat anxiety behaviors^{27,63,64}. In both EPMT (Fig. 1C) and OFT (Fig. 1D), LPS induced significantly increased time stay in closed arm in EPMT (anxiety behaviors) by 46% (162 vs. 237) and immobile time in OPT by 130% (82 vs. 189) respectively. Intranasal dantrolene nanoparticle pretreatment robustly inhibited the increased time stay in closed arm in EPMT by 29% (237 vs. 169) and immobile time in OPT by 40% (189 vs. 114). In contrast, the intranasal dantrolene nanoparticles vehicle control did not demonstrate the same inhibitory effects on depression behaviors.

In the open field test, the less central zone distance mice traveled and had a lower moving speed, the more severe the anxiety behavior (supplemental Fig. 2). Compared to the control without treatment, one-time LPS treatment significantly decreased mean speed (anxiety behavior) but not traveled zone distance. Intranasal dantrolene nanoparticles tended to inhibit LPS-induced decrease of travel zone distance and mean speed (Supplemental Fig. 2).

Intranasal dantrolene nanoparticle pretreatment significantly inhibited LPS-induced helplessness and anxiety behaviors primarily in female mice.

We further analyze the effects of sex on neuroprotective effects of intranasal dantrolene nanoparticles on helplessness and anxiety behavior. As demonstrated in Fig. 2, intranasal dantrolene nanoparticles but not its vehicle control primarily inhibited helpless behavior determined by both FST (Fig. 2A) and TST (Fig. 2B) in female but not male mice. For anxiety behavior, although intranasal dantrolene nanoparticle but not vehicle control inhibited LPS-induced anxiety behavior determined by EPMT (Fig. 2C) in male mice, the inhibitory effects of dantrolene on anxiety behaviors were most significant in female mice determined by both EPMT (Fig. 2C) and OFT (Fig. 2D).

Intranasal dantrolene nanoparticles significantly inhibited LPS-induced pathological elevation of pyroptosis-related inflammation cytokines in blood and brains.

Compared to control without treatment, IP injection of LPS (5mg/kg) for one time significantly increased blood concentrations of IL-1 β by 147% (Fig. 3A, 136 vs. 336) and IL-18 by 67% (Fig. 3B, 233 vs. 390). Intranasal dantrolene nanoparticles but not its vehicle control significantly inhibited the increased IL-1 β by 46% (336 vs. 183) and elevated IL-18 by 23% (Fig. 3B, 390 vs. 299). Furthermore, intranasal dantrolene nanoparticles significantly inhibited LPS-induced elevation of IL-1 β and IL-18 proteins in both blood (Fig. 3A, B) and in brains (Fig. 3C, D, supplemental Figs. 3 and 4).

Intranasal dantrolene nanoparticles inhibited LPS-induced programmed cell death by pyroptosis in mice brains.

Compared to control mice without treatment, LPS treatment increased the protein levels of pyroptosis pathway activation (NLRP3, caspase-1 and N terminal GSDMD) in mice brains. Intranasal dantrolene nanoparticles significantly inhibited increase of Caspase-1 (P20), a biomarker of programmed cell death by pyroptosis (Fig. 4C, D, supplemental Fig. 6), and trended to inhibit LPS-induced elevation of pyroptosis pathway activation proteins (Fig. 4, A and B, supplemental Fig. 5, NLRP-3 and Fig. 4E and F, supplemental Fig. 7, N terminal GSDMD (GSDMD-NT))

Intranasal dantrolene nanoparticles significantly inhibited LPS-induced synapse protein loss in the mice brains.

Compared to control without treatment, LPS significantly decreased the synapse proteins of PSD-95 by 45% (1.322 vs. 0.726, Fig. 5, A, C, supplemental Fig. 8) and synapsin-1 by 37% (0.925 vs. 0.579, Fig. 5, B, D, supplemental Fig. 9) in mice brains. Intranasal dantrolene nanoparticles but not vehicle control pretreatment for 4 weeks significantly inhibited the pathological reduction of synapse proteins of PSD-95 by 77% (0.726 vs. 1.286, Fig. 5A, C, supplemental Fig. 8) and synapsin-1 by 76% (0.579 vs. 1.021, Fig. 5B and D, supplemental Fig. 9).

Discussion

There is an urgent need for new therapeutic interventions to prevent or treat MDD^{3,65}, and anxiety⁵ psychiatric disorders, especially those drug-resistant and recurrent depression and anxiety^{5,16,66}. This study has demonstrated that intranasal dantrolene nanoparticles are capable of ameliorating helplessness and anxiety behaviors in adult mice, associated with its ability to inhibit pathological elevation of pyroptosis related cytokines (IL-1 β and IL-18) in blood, pyroptosis biomarker caspase-1 (P20) and synapse proteins loss in brains. Considering that upstream Ca²⁺ dysregulation plays an important role in the pathology of depression and anxiety, evidenced by the effectiveness of ketamine and esketamine in treating depression and anxiety resistant to traditional drug treatments^{14,16}, a new class of drugs, such as dantrolene, could be developed with a mechanism to correct the disruption of upstream Ca²⁺ dysregulation and associated downstream pathological inflammation and pyroptosis in psychiatric disorders.

Increasing studies suggest that inflammation is an important pathology causing MDD and anxiety and could be a target for effective treatments^{67–70}. Intracellular Ca²⁺ dysregulation has been proposed as the upstream cause of downstream mitochondria dysfunction, oxidative stress, and inflammation in MDD^{25,71,72} and anxiety^{38,73}. Inhibition of upstream Ca²⁺ dysregulation through inhibiting over-activation of RyRs has been shown to suppress inflammation in Gulf War illness characterized by depression and dementia²⁸. Although dantrolene has been shown to inhibit pathological inflammation with increased cytokines in diabetes^{74,75}, sepsis^{76,77}, and COVID-19 infection^{78,79}, its effects to inhibit Ca²⁺ dysregulation and associated inflammation for treating depression and anxiety behaviors have not yet been investigated until now and studied herewith.

Several animal models to establish depression and anxiety behaviors have been suggested based on the proposed neurobiology mechanisms, including altered neurotransmission, HPA axis abnormalities involved in chronic stress, inflammation, reduced neuroplasticity, and network dysfunction^{80–82}. Induction of inflammation in animals has been increasingly used to establish depression and anxiety animal models, especially using LPS to induce inflammation, depression, and anxiety behaviors to test drug treatment efficacy^{37,71,83–86}. The common approach of LPS administration is intraperitoneal injection because of its ease and feasibility. The dose and duration of IP injection of LPS to establish depression or anxiety behaviors has been varied but appears to be dose dependent. The high dose of LPS at 5 mg/kg, administered once, seems to be dependable in inducing inflammation and establishing depression behavior⁷¹. Our study confirmed the efficiency of a one-time administration of IP LPS (5 mg/kg) to induce inflammation and depression and anxiety behavior in adult mice consistently. Accordingly, the LPS-induced inflammation-mediated depression behaviors are adequate to evaluate the therapeutic effects of dantrolene to treat depression. Our results demonstrated robust inhibition of LPS-induced inflammation and associated helplessness and anxiety behaviors by intranasal dantrolene nanoparticles pretreatment in adult mice. In addition to the protective effects of dantrolene against memory loss in various AD animal models^{52,87–89}, intranasal dantrolene nanoparticles also significantly inhibited helplessness and anxiety behaviors, and associated inflammation and pyroptosis, suggesting that pathological inflammation and pyroptosis play a critical role in both cognitive dysfunction and psychiatric disorders. Drugs that target inflammation pathology should be developed to treat both memory loss and psychiatric disorders in AD patients. Nevertheless, intranasal dantrolene nanoparticles significantly inhibited LPS-induced pathological elevation of pyroptosis related inflammation cytokines (IL-1 β and IL-18) in blood and ameliorated both depression and anxiety behavior in adult mice, suggesting that intranasal dantrolene nanoparticles could be developed as an effective drug to treat depression and/or anxiety in major depression disorder (MDD) patients potentially by its inhibition of inflammation and associated programmed cell death by pyroptosis.

MDD affects female patients twice as much as male^{90,91}. The proposed mechanisms for this sex difference include the effects of estrogen⁹², serotonin, and tryptophan metabolism⁹³, different stress reactions⁹¹, etc. An important finding in this study is that intranasal dantrolene nanoparticles are more effective in ameliorating helplessness and anxiety behaviors in female than in male mice. Our result is consistent with MDD being more prevalent in female mice than in male. Also, the more significant inhibition of inflammation associated with helplessness and anxiety behavior in female mice by intranasal dantrolene nanoparticles suggested that dantrolene may inhibit critical pathology and etiology contributing to depression and anxiety behaviors. Although the exact mechanism is unclear, we propose that dantrolene inhibited the upper stream critical Ca²⁺ dysregulation and associated inflammation and associated programmed neuron death by pyroptosis and synapse protein loss.

Intranasal administration of drugs, especially in a nanoparticle formulation, significantly promotes drugs that bypass the blood-brain barrier (BBB) and penetrate the CNS, with reduced peripheral toxicity^{94–96}. Our recent research work indicated that intranasal dantrolene nanoparticles achieved higher therapeutic

efficacy in the brain compared to oral and subcutaneous forms of administration, with minimal or no side effects after chronic use^{52,53,97}. Intranasal dantrolene nanoparticles significantly ameliorated memory loss in adult 5XFAD mice as a disease-modifying drug⁵². Increasing studies suggest ryanodine receptor overactivation and associated Ca^{2+} dysregulation is an upstream critical pathology leading to multiple downstream pathologies including mitochondria dysfunction⁹⁸, oxidative stresses⁹⁹, pathological inflammation¹⁰⁰, and neuron damage by pyroptosis¹⁰¹. Eventually, these pathologies result in depression and/or anxiety psychiatric disorders^{34,70,102}. This study demonstrated that inhibition of RyRs overactivation by dantrolene inhibited pathological inflammation, synapse proteins destruction, and ameliorated depression and anxiety behavior robustly. This study further strengthens the indication that upstream RyRs overactivation and Ca^{2+} dysregulation and associated downstream pathological inflammation and synapse destruction play important roles in depression and anxiety psychiatric disorders. Like esketamine^{22,103}, the intranasal dantrolene nanoparticles could become an effective disease-modifying drug treatment for both depression and anxiety psychiatric disorders and need to be investigated in future clinical studies.

Since depression and anxiety psychiatric disorders are chronic diseases, they require long-term drug treatments. Accordingly, proposed drugs must limit side effects or organ toxicity with chronic treatment. The major advantage of using intranasal dantrolene nanoparticles, in comparison to commonly used oral or intravenous approaches, is that it significantly increases the brain/blood concentration ratio of dantrolene^{52,53}, especially in aged mice⁹⁷. This promotes its CNS therapeutic effects, while minimizing its side effects or organ toxicity⁵². Our previous study demonstrated no side effects on nose structure and smell function^{52,104}, liver structure⁵² and function, or muscle function^{51,52,87} after up to 10 months of chronic treatment in adult 5XFAD mice⁵², suggesting that intranasal dantrolene nanoparticles are safe to be used chronically in animals. Chronic use of dantrolene in human patients needs to be investigated further.

This study has the following limitations: 1. The mice are from 5 to 10 months old. Although they are considered adult mice, future studies need to focus on different age groups, especially in aged mice, considering the high prevalence of psychiatric disorders in the aged population. 2). We were unable to measure the changes of cytosol versus mitochondria Ca^{2+} levels in the brain tissue due to technological challenges. However, dantrolene has been shown to inhibit LPS or AD gene mutation-induced overactivation of RyRs and associated Ca^{2+} dysregulation in different cell culture models^{105,106}. 3). We did not measure the contents of reactive oxygen species (ROS) concentrations in the brain, which is usually the upstream pathology to activate NLRP3 inflammasome¹⁰⁷. 4). We did not measure other biomarkers demonstrating effects of intranasal dantrolene nanoparticles on programmed cell death by pyroptosis in brains. 6). We did not study the dose-response of dantrolene to treat depression and anxiety behaviors. Physiological Ca^{2+} release from ER is important for many physiological functions in cells, which means over-inhibition of calcium release from the ER may be harmful to cells, as we

described previously. The adequate dose of intranasal dantrolene nanoparticles to treat psychiatric disorders must be investigated thoroughly before its clinical use in patients.

In conclusion, this study demonstrated that intranasal dantrolene nanoparticles significantly ameliorated inflammation-mediated depression and anxiety behaviors in adult mice. This neuroprotective effect against depression and anxiety behaviors was associated with its robust inhibition of pathological elevation of pyroptosis-related inflammation cytokines in blood and the synapse destruction in the brains. This study may inspire future studies to repurpose intranasal dantrolene nanoparticles in treating depression and anxiety psychiatric disorders.

Declarations

Conflict of Interests

Drs. Huafeng Wei and Ge Liang are listed as inventors of patent applications entitled “Intranasal Administration of Dantrolene for Treatment of Alzheimer’s Disease” in multiple countries by The Trustees of the University of Pennsylvania.

Author contributions

H.W. conceived and designed the study. J.L., Y.L, P.B. J.G, L.S.L, Y.Y., G.L, H.W. conducted experiments, acquired and analyzed the data, J.L., Y.L, P.B. J.G, L.S.L, Y.Y., G.L, H.W. analyzed data and contributed to the manuscript preparation. H.W. wrote the manuscript. All the authors reviewed and approved the final manuscript.

Acknowledgments

This work was supported by grants to HW from the National Institute on Aging (R01AG061447) and NIA R01 Supplemental (3R01AG061447-03S1). The research was performed in the lab of Dr. Huafeng Wei and should be attributed to the Department of Anesthesiology, University of Pennsylvania. We appreciate the technical support from Rebecca Chae from Rowan University, New Jersey, U.S.A. and Kyulee Kim from UPENN, Pennsylvania, U.S.A.

References

1. Herrman H, Kieling C, McGorry P, Horton R, Sargent J, Patel V: Reducing the global burden of depression: a Lancet-World Psychiatric Association Commission. *Lancet* 2019; 393: e42-e43
2. Rikhani K, Vas C, Jha MK: Approach to Diagnosis and Management of Treatment-Resistant Depression. *Psychiatr Clin North Am* 2023; 46: 247–259

3. Belge JB, Sabbe ACF, Sabbe B: An update on pharmacotherapy for recurrent depression in 2022. *Expert Opin Pharmacother* 2023; 1–8
4. Gururajan A, Reif A, Cryan JF, Slattery DA: The future of rodent models in depression research. *Nat Rev Neurosci* 2019; 20: 686–701
5. Szuhany KL, Simon NM: Anxiety Disorders: A Review. *JAMA* 2022; 328: 2431–2445
6. Jarkas DA, Villeneuve AH, Daneshmend AZB, Villeneuve PJ, McQuaid RJ: Sex differences in the inflammation-depression link: A systematic review and meta-analysis. *Brain Behav Immun* 2024; 121: 257–268
7. Altemus M, Sarvaiya N, Neill Epperson C: Sex differences in anxiety and depression clinical perspectives. *Front Neuroendocrinol* 2014; 35: 320–30
8. Somers JM, Goldner EM, Waraich P, Hsu L: Prevalence and incidence studies of anxiety disorders: a systematic review of the literature. *Can J Psychiatry* 2006; 51: 100–13
9. Bruton AM, Wesemann DG, Machingo TA, Majak G, Johnstone JM, Marshall RD: Ketamine for mood disorders, anxiety, and suicidality in children and adolescents: a systematic review. *Eur Child Adolesc Psychiatry* 2024
10. Ait Tayeb AEK, Poinsignon V, Chappell K, Bouligand J, Becquemont L, Verstuyft C: Major Depressive Disorder and Oxidative Stress: A Review of Peripheral and Genetic Biomarkers According to Clinical Characteristics and Disease Stages. *Antioxidants (Basel)* 2023; 12
11. Cowen PJ: SSRIs in the Treatment of Depression: A Pharmacological CUL-DE-SAC? *Curr Top Behav Neurosci* 2024; 66: 1–19
12. Malena K, Rao S, Mosler C: Review of Current Clinical Options for the Management of Behavioral and Psychological Symptoms of Dementia. *Sr Care Pharm* 2024; 39: 300–310
13. Nuss P, Ferreri F, Bourin M: An update on the anxiolytic and neuroprotective properties of etifoxine: from brain GABA modulation to a whole-body mode of action. *Neuropsychiatr Dis Treat* 2019; 15: 1781–1795
14. Paganin W, Signorini S, Leccese V, Sciarretta A: [Treatment-resistant depression. From classification to new therapies.]. *Riv Psichiatri* 2022; 57: 258–272
15. Robertson S, Peacock EE, Scott R: Benzodiazepine Use Disorder: Common Questions and Answers. *Am Fam Physician* 2023; 108: 260–266
16. Tabaac BJ, Shinozuka K, Arenas A, Beutler BD, Cherian K, Evans VD et al: Psychedelic Therapy: A Primer for Primary Care Clinicians-Historical Perspective and Overview. *Am J Ther* 2024; 31: e97-e103
17. Sarawagi A, Soni ND, Patel AB: Glutamate and GABA Homeostasis and Neurometabolism in Major Depressive Disorder. *Front Psychiatry* 2021; 12: 637863
18. Ren L: The mechanistic basis for the rapid antidepressant-like effects of ketamine: From neural circuits to molecular pathways. *Prog Neuropsychopharmacol Biol Psychiatry* 2024; 129: 110910
19. Costi S: Ketamine for Major Depressive Disorder. *Curr Top Behav Neurosci* 2023

20. Tully JL, Dahlen AD, Haggarty CJ, Schioth HB, Brooks S: Ketamine treatment for refractory anxiety: A systematic review. *Br J Clin Pharmacol* 2022; 88: 4412–4426
21. Matveychuk D, Thomas RK, Swainson J, Khullar A, MacKay MA, Baker GB et al: Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers. *Ther Adv Psychopharmacol* 2020; 10: 2045125320916657
22. Rosso G, d'Andrea G, Barlati S, Di Nicola M, Andriola I, Marcatili M et al: Esketamine Treatment Trajectory of Patients with Treatment-Resistant Depression in the Mid and Long-Term Run: Data from REAL-ESK Study Group. *Curr Neuropharmacol* 2025; 23: e1570159X337670
23. Deutschenbaur L, Beck J, Kiyhankhadiv A, Muhlhauser M, Borgwardt S, Walter M et al: Role of calcium, glutamate and NMDA in major depression and therapeutic application. *Prog Neuropsychopharmacol Biol Psychiatry* 2016; 64: 325–33
24. Fries GR, Saldana VA, Finnstein J, Rein T: Molecular pathways of major depressive disorder converge on the synapse. *Mol Psychiatry* 2023; 28: 284–297
25. Garrosa-Jimenez J, Sanchez Carro Y, Ovejero-Benito MC, Del Sastre E, Garcia AG, Lopez MG et al: Intracellular calcium and inflammatory markers, mediated by purinergic stimulation, are differentially regulated in monocytes of patients with major depressive disorder. *Neurosci Lett* 2021; 765: 136275
26. Valiati FE, Feiten JG, Gea LP, Silveira EMJ, Scotton E, Caldieraro MA et al: Inflammation and damage-associated molecular patterns in major psychiatric disorders. *Trends Psychiatry Psychother* 2022
27. Wang Y, Wu LH, Hou F, Wang ZJ, Wu MN, Holscher C et al: Mitochondrial calcium uniporter knockdown in hippocampal neurons alleviates anxious and depressive behavior in the 3XTG Alzheimer's disease mouse model. *Brain Res* 2024; 1840: 149060
28. Phillips KF, Santos E, Blair RE, Deshpande LS: Targeting Intracellular Calcium Stores Alleviates Neurological Morbidities in a DFP-Based Rat Model of Gulf War Illness. *Toxicol Sci* 2019; 169: 567–578
29. Cardon I, Grobecker S, Kucukoktay S, Bader S, Jahner T, Nothdurfter C et al: Mitochondrial and Cellular Function in Fibroblasts, Induced Neurons, and Astrocytes Derived from Case Study Patients: Insights into Major Depression as a Mitochondria-Associated Disease. *Int J Mol Sci* 2024; 25
30. Song Y, Cao H, Zuo C, Gu Z, Huang Y, Miao J et al: Mitochondrial dysfunction: A fatal blow in depression. *Biomed Pharmacother* 2023; 167: 115652
31. Lindqvist D, Dhabhar FS, James SJ, Hough CM, Jain FA, Bersani FS et al: Oxidative stress, inflammation and treatment response in major depression. *Psychoneuroendocrinology* 2017; 76: 197–205
32. Zhou XY, Thai M, Roediger D, Mueller BA, Cullen KR, Klimes-Dougan B et al: Mitochondrial health, NLRP3 inflammasome activation, and white matter integrity in adolescent mood disorders: A pilot study. *J Affect Disord* 2023; 340: 149–159
33. Cao H, Yang D, Nie K, Lin R, Peng L, Zhou X et al: Hesperidin may improve depressive symptoms by binding NLRP3 and influencing the pyroptosis pathway in a rat model. *Eur J Pharmacol* 2023; 952:

34. Li S, Sun Y, Song M, Song Y, Fang Y, Zhang Q et al: NLRP3/caspase-1/GSDMD-mediated pyroptosis exerts a crucial role in astrocyte pathological injury in mouse model of depression. *JCI Insight* 2021; 6
35. Simon MS, Schiweck C, Arteaga-Henriquez G, Poletti S, Haarman BCM, Dik WA et al: Monocyte mitochondrial dysfunction, inflammaging, and inflammatory pyroptosis in major depression. *Prog Neuropsychopharmacol Biol Psychiatry* 2021; 111: 110391
36. Kaufmann FN, Costa AP, Ghisleni G, Diaz AP, Rodrigues ALS, Peluffo H et al: NLRP3 inflammasome-driven pathways in depression: Clinical and preclinical findings. *Brain Behav Immun* 2017; 64: 367–383
37. Vogelzangs N, de Jonge P, Smit JH, Bahn S, Penninx BW: Cytokine production capacity in depression and anxiety. *Transl Psychiatry* 2016; 6: e825
38. Zhang LM, Zhang DX, Song RX, Lv JM, Wang LY, Wu ZY et al: IL-18BP Alleviates Anxiety-Like Behavior Induced by Traumatic Stress via Inhibition of the IL-18R-NLRP3 Signaling Pathway in a Mouse Model of Hemorrhagic Shock and Resuscitation. *Mol Neurobiol* 2023; 60: 382–394
39. Bhatt S, Kanoujia J, Mohana Lakshmi S, Patil CR, Gupta G, Chellappan DK et al: Role of Brain-Gut-Microbiota Axis in Depression: Emerging Therapeutic Avenues. *CNS Neurol Disord Drug Targets* 2023; 22: 276–288
40. Anand N, Gorantla VR, Chidambaram SB: The Role of Gut Dysbiosis in the Pathophysiology of Neuropsychiatric Disorders. *Cells* 2022; 12
41. Ratto D, Joyner RW: Dantrolene, StatPearls. Treasure Island (FL), 2020
42. Nakayama R, Yano T, Ushijima K, Abe E, Terasaki H: Effects of dantrolene on extracellular glutamate concentration and neuronal death in the rat hippocampal CA1 region subjected to transient ischemia. *Anesthesiology* 2002; 96: 705–10
43. Wei HF, Perry DC: Dantrolene is cytoprotective in two models of neuronal cell death. *Journal of Neurochemistry* 1996; 67: 2390–2398
44. Chen X, Wu J, Lvovskaya S, Herndon E, Supnet C, Bezprozvanny I: Dantrolene is neuroprotective in Huntington's disease transgenic mouse model. *Mol Neurodegener* 2011; 6: 81
45. Chen X, Tang TS, Tu H, Nelson O, Pook M, Hammer R et al: Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia type 3. *J Neurosci* 2008; 28: 12713–24
46. Rothstein JD, Kuncl RW: Neuroprotective strategies in a model of chronic glutamate-mediated motor neuron toxicity. *J Neurochem* 1995; 65: 643–51
47. Royero PX, Higa GSV, Kosteki DS, Dos Santos BA, Almeida C, Andrade KA et al: Ryanodine receptors drive neuronal loss and regulate synaptic proteins during epileptogenesis. *Exp Neurol* 2020; 327: 113213
48. Keshavarz M, Fotouhi M, Rasti A: Dantrolene: A Selective Ryanodine Receptor Antagonist, Protects Against Pentylene-tetrazole-Induced Seizure in Mice. *Acta Med Iran* 2016; 54: 555–561

49. Frandsen A, Schousboe A: Mobilization of dantrolene-sensitive intracellular calcium pools is involved in the cytotoxicity induced by quisqualate and N-methyl-D-aspartate but not by 2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionate and kainate in cultured cerebral cortical neurons. *Proc Natl Acad Sci U S A*. 1992; 89: 2590–2594
50. Chen T, Cheng L, Ma J, Yuan J, Pi C, Xiong L et al: Molecular mechanisms of rapid-acting antidepressants: New perspectives for developing antidepressants. *Pharmacol Res* 2023; 194: 106837
51. Vera R, Hong N, Jiang B, Liang G, Eckenhoff MF, Kincaid HJ et al: Effects of intranasal dantrolene nanoparticles on brain concentration and behavior in PS19 tau transgenic mice. *Res Sq* 2023
52. Shi Y, Zhang L, Gao X, Zhang J, Ben Abou M, Liang G et al: Intranasal Dantrolene as a Disease-Modifying Drug in Alzheimer 5XFAD Mice. *J Alzheimers Dis* 2020; 76: 1375–1389
53. Wang J, Shi Y, Yu S, Wang Y, Meng Q, Liang G et al: Intranasal administration of dantrolene increased brain concentration and duration. *PLoS One* 2020; 15: e0229156
54. Ueno H, Takahashi Y, Murakami S, Wani K, Matsumoto Y, Okamoto M et al: Effect of simultaneous testing of two mice in the tail suspension test and forced swim test. *Sci Rep* 2022; 12: 9224
55. Can A, Dao DT, Terrillion CE, Piantadosi SC, Bhat S, Gould TD: The tail suspension test. *J Vis Exp* 2012: e3769
56. Jones SK, McCarthy DM, Vied C, Stanwood GD, Schatschneider C, Bhide PG: Transgenerational transmission of aspartame-induced anxiety and changes in glutamate-GABA signaling and gene expression in the amygdala. *Proc Natl Acad Sci U S A* 2022; 119: e2213120119
57. Cho WH, Noh K, Lee BH, Barcelon E, Jun SB, Park HY et al: Hippocampal astrocytes modulate anxiety-like behavior. *Nat Commun* 2022; 13: 6536
58. Joseph DJ, Liu C, Peng J, Liang G, Wei H: Isoflurane mediated neuropathological and cognitive impairments in the triple transgenic Alzheimer's mouse model are associated with hippocampal synaptic deficits in an age-dependent manner. *PLoS One* 2019; 14: e0223509
59. Liang G, Ward C, Peng J, Zhao YF, Huang BS, Wei HF: Isoflurane Causes Greater Neurodegeneration Than an Equivalent Exposure of Sevoflurane in the Developing Brain of Neonatal Mice. *Anesthesiology* 2010; 112: 1325–1334
60. Wang Y, Liang G, Liang S, Mund R, Shi Y, Wei H: Dantrolene Ameliorates Impaired Neurogenesis and Synaptogenesis in Induced Pluripotent Stem Cell Lines Derived from Patients with Alzheimer's Disease. *Anesthesiology* 2020; 132: 1062–1079
61. Liu QF, Choi H, Son T, Kim YM, Kanmani S, Chin YW et al: Co-Treatment with the Herbal Medicine SIP3 and Donepezil Improves Memory and Depression in the Mouse Model of Alzheimer's Disease. *Curr Alzheimer Res* 2022; 19: 246–263
62. Amada N, Hirose T, Suzuki M, Kakumoto Y, Futamura T, Maeda K et al: Synergistic anti-depressive effect of combination treatment of Brexpiprazole and selective serotonin reuptake inhibitors on forced swimming test in mice. *Neuropsychopharmacol Rep* 2023; 43: 132–136

63. Varkonyi D, Torok B, Sipos E, Fazekas CL, Banrevi K, Correia P et al: Investigation of Anxiety- and Depressive-like Symptoms in 4- and 8-Month-Old Male Triple Transgenic Mouse Models of Alzheimer's Disease. *Int J Mol Sci* 2022; 23
64. Pentkowski NS, Rogge-Obando KK, Donaldson TN, Bouquin SJ, Clark BJ: Anxiety and Alzheimer's disease: Behavioral analysis and neural basis in rodent models of Alzheimer's-related neuropathology. *Neurosci Biobehav Rev* 2021; 127: 647–658
65. Brady LS, Lisanby SH, Gordon JA: New directions in psychiatric drug development: promising therapeutics in the pipeline. *Expert Opin Drug Discov* 2023: 1–16
66. Jha MK, Mathew SJ: Pharmacotherapies for Treatment-Resistant Depression: How Antipsychotics Fit in the Rapidly Evolving Therapeutic Landscape. *Am J Psychiatry* 2023; 180: 190–199
67. Han Q, Li W, Chen P, Wang L, Bao X, Huang R et al: Microglial NLRP3 inflammasome-mediated neuroinflammation and therapeutic strategies in depression. *Neural Regen Res* 2024; 19: 1890–1898
68. Su WJ, Hu T, Jiang CL: Cool the Inflamed Brain: A Novel Anti-inflammatory Strategy for the Treatment of Major Depressive Disorder. *Curr Neuropharmacol* 2024; 22: 810–842
69. Chin Fatt CR, Mayes TL, Trivedi MH: Immune Dysregulation in Treatment-Resistant Depression: Precision Approaches to Treatment Selection and Development of Novel Treatments. *Psychiatr Clin North Am* 2023; 46: 403–413
70. Guo B, Zhang M, Hao W, Wang Y, Zhang T, Liu C: Neuroinflammation mechanisms of neuromodulation therapies for anxiety and depression. *Transl Psychiatry* 2023; 13: 5
71. Arioiz BI, Tastan B, Tarakcioglu E, Tufekci KU, Olcum M, Ersoy N et al: Melatonin Attenuates LPS-Induced Acute Depressive-Like Behaviors and Microglial NLRP3 Inflammasome Activation Through the SIRT1/Nrf2 Pathway. *Front Immunol* 2019; 10: 1511
72. Resende R, Fernandes T, Pereira AC, De Pascale J, Marques AP, Oliveira P et al: Mitochondria, endoplasmic reticulum and innate immune dysfunction in mood disorders: Do Mitochondria-Associated Membranes (MAMs) play a role? *Biochim Biophys Acta Mol Basis Dis* 2020; 1866: 165752
73. Zhou GQ, Wang X, Gao P, Qin TZ, Guo L, Zhang ZW et al: Intestinal microbiota via NLRP3 inflammasome dependent neuronal pyroptosis mediates anxiety-like behaviour in mice exposed to 3.5 GHz radiofrequency radiation. *Sci Total Environ* 2024; 927: 172391
74. Clark AL, Kanekura K, Lavagnino Z, Spears LD, Abreu D, Mahadevan J et al: Targeting Cellular Calcium Homeostasis to Prevent Cytokine-Mediated Beta Cell Death. *Sci Rep* 2017; 7: 5611
75. Johnson JD, Han Z, Otani K, Ye H, Zhang Y, Wu H et al: RyR2 and calpain-10 delineate a novel apoptosis pathway in pancreatic islets. *J Biol Chem* 2004; 279: 24794–802
76. Fischer DR, Sun X, Williams AB, Gang G, Pritts TA, James JH et al: Dantrolene reduces serum TNFalpha and corticosterone levels and muscle calcium, calpain gene expression, and protein breakdown in septic rats. *Shock* 2001; 15: 200–7

77. Hotchkiss RS, Karl IE: Dantrolene ameliorates the metabolic hallmarks of sepsis in rats and improves survival in a mouse model of endotoxemia. *Proc Natl Acad Sci U S A*. 1994; 91: 3039–3043
78. Al-Kuraishy HM, Al-Gareeb AI, El-Bouseary MM, Alexiou A, Papadakis M, Batiha GE: Calpain/calpstatin pathway in COVID-19: Role of dantrolene. *J Cell Mol Med* 2024; 28: e18005
79. Alkazmi L, Al-Kuraishy HM, Al-Gareeb AI, El-Bouseary MM, Ahmed EA, Batiha GE: Dantrolene and ryanodine receptors in COVID-19: The daunting task and neglected warden. *Clin Exp Pharmacol Physiol* 2023
80. Villas Boas GR, Boerngen de Lacerda R, Paes MM, Gubert P, Almeida W, Rescia VC et al: Molecular aspects of depression: A review from neurobiology to treatment. *Eur J Pharmacol* 2019; 851: 99–121
81. Dean J, Keshavan M: The neurobiology of depression: An integrated view. *Asian J Psychiatr* 2017; 27: 101–111
82. Sapolsky RM: Psychiatric distress in animals versus animal models of psychiatric distress. *Nat Neurosci* 2016; 19: 1387–1389
83. Mahdirejei HA, Peeri M, Azarbayjani MA, Fattahi Masrour F: Fluoxetine combined with swimming exercise synergistically reduces lipopolysaccharide-induced depressive-like behavior by normalizing the HPA axis and brain inflammation in mice. *Pharmacol Biochem Behav* 2023; 232: 173640
84. Zhuo R, Cheng X, Luo L, Yang L, Zhao Y, Zhou Y et al: Cinnamic Acid Improved Lipopolysaccharide-Induced Depressive-Like Behaviors by Inhibiting Neuroinflammation and Oxidative Stress in Mice. *Pharmacology* 2022; 107: 281–289
85. Li W, Ali T, He K, Liu Z, Shah FA, Ren Q et al: Ibrutinib alleviates LPS-induced neuroinflammation and synaptic defects in a mouse model of depression. *Brain Behav Immun* 2021; 92: 10–24
86. Li W, Xu Y, Liu Z, Shi M, Zhang Y, Deng Y et al: TRPV4 inhibitor HC067047 produces antidepressant-like effect in LPS-induced depression mouse model. *Neuropharmacology* 2021; 201: 108834
87. Peng J, Liang G, Inan S, Wu Z, Joseph DJ, Meng Q et al: Dantrolene ameliorates cognitive decline and neuropathology in Alzheimer triple transgenic mice. *Neurosci Lett* 2012; 516: 274–9
88. Chakroborty S, Briggs C, Miller MB, Goussakov I, Schneider C, Kim J et al: Stabilizing ER Ca²⁺ channel function as an early preventative strategy for Alzheimer's disease. *PLoS One* 2012; 7: e52056
89. Oules B, Del Prete D, Greco B, Zhang X, Lauritzen I, Sevalle J et al: Ryanodine receptor blockade reduces amyloid-beta load and memory impairments in Tg2576 mouse model of Alzheimer disease. *J Neurosci* 2012; 32: 11820–34
90. Shors TJ, Millon EM, Chang HY, Olson RL, Alderman BL: Do sex differences in rumination explain sex differences in depression? *J Neurosci Res* 2017; 95: 711–718
91. Fernandez-Guasti A, Fiedler JL, Herrera L, Handa RJ: Sex, stress, and mood disorders: at the intersection of adrenal and gonadal hormones. *Horm Metab Res* 2012; 44: 607–18

92. Iqbal J, Huang GD, Xue YX, Yang M, Jia XJ: Role of estrogen in sex differences in memory, emotion and neuropsychiatric disorders. *Mol Biol Rep* 2024; 51: 415
93. Songtachalert T, Roomruangwong C, Carvalho AF, Bourin M, Maes M: Anxiety Disorders: Sex Differences in Serotonin and Tryptophan Metabolism. *Curr Top Med Chem* 2018; 18: 1704–1715
94. Maher R, Moreno-Borralló A, Jindal D, Mai BT, Ruiz-Hernandez E, Harkin A: Intranasal Polymeric and Lipid-Based Nanocarriers for CNS Drug Delivery. *Pharmaceutics* 2023; 15
95. Fonseca LC, Lopes JA, Vieira J, Viegas C, Oliveira CS, Hartmann RP et al: Intranasal drug delivery for treatment of Alzheimer's disease. *Drug Deliv Transl Res* 2021; 11: 411–425
96. Hanson LR, Frey WH, 2nd: Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. *BMC Neurosci* 2008; 9 Suppl 3: S5
97. Vera R, Hong N, Jiang B, Liang G, Eckenhoﬀ MF, Kincaid HJ et al: Effects of Intranasal Dantrolene Nanoparticles on Brain Concentration and Behavior in PS19 Tau Transgenic Mice. *J Alzheimers Dis* 2024
98. Garbincius JF, Elrod JW: Mitochondrial calcium exchange in physiology and disease. *Physiol Rev* 2022; 102: 893–992
99. Gleitze S, Ramirez OA, Vega-Vasquez I, Yan J, Lobos P, Bading H et al: Ryanodine Receptor Mediated Calcium Release Contributes to Ferroptosis Induced in Primary Hippocampal Neurons by GPX4 Inhibition. *Antioxidants (Basel)* 2023; 12
100. Triantafilou K, Hughes TR, Triantafilou M, Morgan BP: The complement membrane attack complex triggers intracellular Ca²⁺ + fluxes leading to NLRP3 inflammasome activation. *J Cell Sci* 2013; 126: 2903–13
101. Wongpun J, Chanmanee T, Tocharus J, Chokchaisiri R, Chaichompoo W, Suksamrarn A et al: The potential effects of festidinol treatment against the NLRP3 inflammasome and pyroptosis in D-galactose and aluminum chloride-induced Alzheimer's-like pathology in mouse brain. *Int Immunopharmacol* 2023; 119: 110181
102. Wan T, Li X, Fu M, Gao X, Li P, Guo W: NLRP3-Dependent Pyroptosis: A Candidate Therapeutic Target for Depression. *Front Cell Neurosci* 2022; 16: 863426
103. Fountoulakis KN, Saitis A, Schatzberg AF: Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis. *Am J Psychiatry* 2025: appiajp20240515
104. Jiang B, Shi Y, Abou MB, Xu L, Liang G, Wei H: Effects of chronic intranasal dantrolene on nasal mucosa morphology in mice. *Eur Rev Med Pharmacol Sci* 2022; 26: 198–203
105. Hasko G, Szabo C, Nemeth ZH, Lendvai B, Vizi ES: Modulation by dantrolene of endotoxin-induced interleukin-10, tumour necrosis factor- α and nitric oxide production in vivo and in vitro. *Br J Pharmacol* 1998; 124: 1099–106
106. Zhang IX, Herrmann A, Leon J, Jeyarajan S, Arunagiri A, Arvan P et al: ER stress increases expression of intracellular calcium channel RyR1 to modify Ca(2+) homeostasis in pancreatic beta cells. *J Biol Chem* 2023; 299: 105065

Figures




Figure 1

See image above for figure legend.




Figure 2

See image above for figure legend.




Figure 3. Intranasal Dantrolene Significantly Inhibited lipopolysaccharide-induced pathological elevation of IL-18 and IL-1 β cytokines in the blood and brains. B6SJLF1/J adult mice were pretreated with intranasal dantrolene nanoparticles DAN, 5mg/kg) or vehicle (Veh) control daily, Monday to Friday, for continuous 4 weeks. Mice were then treated with one-time IP injection of lipopolysaccharide (LPS, 5 mg/kg). Mice in control (No Tx) group received no treatments. IL1 β in blood (**A**) and brain (**C**, **E**) and IL18 in blood (**B**) and brains (**D**, **F**) were measured using ELISA assay kit (**A**, **B**) or immunoblotting (**C**-**F**), N=18-20 mice for blood measurement (**A**, **B**) and N=4 brains for immunoblotting (**C**-**F**), Means $\pm$ 95% CI, One-Way ANOVA followed by Tukey post hoc test. **P<0.01, ****P<0.0001 respectively..

Figure 3

See image above for figure legend.




Figure 4

See image above for figure legend.




Figure 5

See image above for figure legend.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [1Supplementaryinformationwtonly2162025Final1.pdf](#)